Conduit Pharmaceuticals

NASDAQ: CDT
Nasdaq Stock Market
Healthcare Biotechnology
Global Rank
#48630
Country Rank
#5865
Market Cap
1.98 M
Price
0.313
Change (%)
11.72%
Volume
251,481

Conduit Pharmaceuticals (NASDAQ: CDT) Stock Split History

Date Split Ratio Multiple Cumulative multiple Type
07/20/2026 1:10 x0.1 x0.0000003333333 Reverse
03/27/2026 1:25 x0.04 x0.000003333333 Reverse
10/13/2025 1:8 x0.125 x0.00008333333 Reverse
05/20/2025 1:15 x0.06666667 x0.0006666667 Reverse
01/27/2025 1:100 x0.010 x0.010 Reverse

Frequently Asked Questions

  • How much would Conduit Pharmaceuticals stock be worth if it never split?
    If Conduit Pharmaceuticals (stock symbol: NASDAQ: CDT) had never undergone any stock splits, its price per share today would be approximately 0.00 USD. This calculation reflects the cumulative effect of all splits, including the most recent split (ratio: 1-for-10) that occurred on 07/20/2026.
  • Conduit Pharmaceuticals (stock symbol: NASDAQ: CDT) has undergone a total of five stock splits. The most recent split occurred on 07/20/2026. One share bought prior to the first split on 01/27/2025 would now equal 0.00 shares.
  • Conduit Pharmaceuticals (stock symbol: NASDAQ: CDT) has undergone five stock splits in its history. The most recent split, a 1-for-100 split, occurred on 07/20/2026. While future splits are not guaranteed, significant increases in stock price could prompt consideration for another split.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.